Asia-Pacific Thyroid Cancer Diagnostics Market – Industry Trends and Forecast to 2030

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Buy Now Buy Now Inquire Before Buying Inquire Before Free Sample Report Free Sample Report

Asia-Pacific Thyroid Cancer Diagnostics Market – Industry Trends and Forecast to 2030

  • Medical Devices
  • Published Report
  • Feb 2023
  • Asia-Pacific
  • 350 Pages
  • No of Tables: 248
  • No of Figures: 47

Asia-Pacific Thyroid Cancer Diagnostics Market, By Product Type (Instruments, Consumables & Accessories), Test Type (Imaging Test, Biopsy, Blood Test, Others), Cancer Type (Papillary Carcinoma, Follicular Carcinoma, Others), Stages (Stage I, Stage II, Stage III, Stage IV), Age Group (Below 21, 21-29, 30-65, 65 and Above), End User (Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales) - Industry Trends and Forecast to 2030.

Asia-Pacific Thyroid Cancer Diagnostics Market

Asia-Pacific Thyroid Cancer Diagnostics Market Analysis and Insights

Increasing awareness about thyroid cancer has enhanced the market demand. The rising healthcare expenditure for better health services also contributes to the market's growth. The major market players focus on various service launches and approvals during this crucial period. In addition, the increase in improved diagnostic processes and techniques also contributes to the rising demand for thyroid cancer diagnostics testing.

Asia-Pacific Thyroid Cancer Diagnostics Market

Asia-Pacific Thyroid Cancer Diagnostics Market

Asia-Pacific thyroid cancer diagnostics market is expected to grow in the forecast period of 2023 to 2030. Data Bridge Market Research analyses that the market is growing with a CAGR of 5.0% in the forecast period of 2023 to 2030 and is expected to reach USD 1,572.00 million by 2030.

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Year

2021 (Customisable to 2020-2015)

Quantitative Units

Revenue in USD Million

Segments Covered

By Product Type (Instruments, Consumables & Accessories), Test Type (Imaging Test, Biopsy, Blood Test, Others), Cancer Type (Papillary Carcinoma, Follicular Carcinoma, Others), Stages (Stage I, Stage II, Stage III, Stage IV), Age Group (Below 21, 21-29, 30-65, 65 and Above), End User (Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales)

Countries Covered

Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific

Market Players Covered

Canon Inc., FUJIFILM Holdings Corporation, F. Hoffmann-La Roche Ltd, Quest Diagnostics Incorporated, Illumina, Koninklijke Philips N.V., Thermo Fisher Scientific Inc., Siemens Healthcare GmbH, Abbott, General Electric Company, BD, QIAGEN, DIASORIN S.P.A., Merck KGaA, Hologic, Myriad Genetics Inc., BIOMERIEUX, FONAR Corp., Time Medical Holding., PlexBio., MinFound Medical Systems Co., Ltd, Medonica Co. LTD, Beijing O&D Biotech Co., Ltd., and SternMed GmbH. among others.

Market Definition

Thyroid cancer is a type of cancer that starts in the thyroid gland. Cancer starts when cells begin to grow out of control. The thyroid gland makes hormones that help regulate your metabolism, heart rate, blood pressure, and body temperature. The thyroid gland is in the front part of the neck, below the thyroid cartilage (Adam's apple). In most people, the thyroid cannot be seen or felt. It is shaped such as a butterfly, with two lobes — the right lobe and the left lobe — joined by a narrow piece of the gland called the isthmus.

Asia-Pacific Thyroid Cancer Diagnostics Market Dynamics

DRIVERS

RISING INCIDENCE AND PREVALENCE OF THYROID NODULES & CANCER

A thyroid nodule is an unusual growth (lump) of thyroid cells in the thyroid gland. Sometimes the normal thyroid soft tissue started to grow, causing these nodules to form. Nodule incidence increases with age and mainly in women, mainly in those with iodine deficiency and after radiation exposure. Although the further complication of these nodules is thyroid cancer, the chances of converting thyroid nodules to thyroid cancer are low. According to an article published in NCBI named "Risk of Malignancy in Thyroid Nodules 4 cm or Larger" in 2017, cancer occurrence after nodules is found in less than 5% of the total nodules cases. Moreover, the thyroid nodules run in the family history and in people whose iodine intake is low.

RISING THYROID CANCER DIAGNOSTIC TESTS

Thyroid ultrasound is a sound wave picture of the thyroid gland taken by a hand-held instrument and translated to a 2-dimensional picture on a monitor. It is used in the diagnosis of tumors, cysts, or goiters of the thyroid and is a painless, no-risk procedure. These tests are used to evaluate structural anomalies, whereas blood tests measuring TSH, T4, and T3 levels are used to examine functional variables. Fine needle biopsy is used in suspicious cases to determine whether a tumor is benign or malignant. Furthermore, the introduction of molecular testing and the genetic prognosis fuel the diagnostic landscape in this market for thyroid cancer diagnostics.

RISING AWARENESS TOWARDS THYROID CANCER

Growing thyroid cancer awareness has led to an increased demand for timely cancer detection, leading to market growth.

Thyroid cancer is one of the major causes of rising mortality rates among U.S. populations worldwide, fueling the market growth over the next five years. Exposure to radiation and a family history of thyroid issues are major risk factors for thyroid cancer. Women are diagnosed with thyroid cancer significantly more than men.

RESTRAINS

HIGH COST OF DIAGNOSTICS PROCEDURE

Cancer diagnostics have become increasingly expensive due to the growing number of thyroid cancer patients and the rising medical device prices. The modern technological devices used in cancer diagnostic is also playing a significant role in the high prices of cancer diagnostics, and high accuracy, in providing a definitive diagnosis for cancer in thyroid nodules. Therefore, the high cost of diagnostics procedures for thyroid cancers is hampering the growth of the market.

The diagnostic products or devices which are used in the detection of cancer are becoming advanced but along with that, the procedure for cancers diagnostics are also costly, which hamper the growth of the thyroid cancer diagnostics market because the devices are used in the process of cancer diagnosis getting more expensive which results to increase in the cost of diagnostics procedure. Thus, the high cost of diagnostics for cancer diagnosis acts as a restraint for the Asia-Pacific thyroid cancer diagnostics market.

TISSUE DAMAGE DUE TO HIGH RADIATION EXPOSURE FROM IMAGING TESTS

High radiation exposure causes significant tissue damage and raise a person's chance of later acquiring cancer. Although it's vital to keep this risk in context, the tiny radiation doses used for imaging tests may marginally raise a person's risk of developing cancer. The amount of radiation a person receives varies on the test's kind, the area of their body that is exposed, their body size, age, and gender, among other things. Imaging examinations that employ radiation should only be performed when necessary because radiation exposure from all sources can mount up over a lifetime and can increase the chance of developing cancer. Other imaging procedures like ultrasound or MRI may also be utilized often.

OPPORTUNITIES

RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT

Across the globe, R&D activities are escalating owing to public health expenditure with economic performances whereas, the healthcare industry ranks second among all industries when it comes to the amount spent on healthcare. Rising healthcare expenditure can result in better provision of R&D opportunities. It is anticipated to upsurge the demand for ovarian cancer diagnostics.

Increasing healthcare expenditure for cancer treatment also helps patients to take hassle-free advanced diagnostics and treatment for fast recovery. Healthcare spending is made up of out-of-pocket payments (people paying for their own care), government expenditure, and sources, including health insurance and activities by Non-Governmental Organizations (NGOs). Due to this increasing healthcare expenditure for cancer treatment, it acts as an opportunity for market growth.

CHALLENGES

STRINGENT REGULATORY FRAMEWORK FOR THE APPROVAL AND COMMERCIALIZATION OF CANCER DIAGNOSTIC PRODUCTS

The stringent regulations for the approval and commercialization of any product in the market are proving to be one of the major challenges for manufacturers of cancer diagnostic products in the U.S. and European region. Every country has regulations and a different body for regulatory procedures.

The potential regulatory pathways are mandatory for clearance, approval, or acceptance of complex signatures by the U.S. Food and Drug Administration (FDA). The regulatory pathways include regulations applicable to In Vitro Diagnostic (IVD) devices, including companion diagnostic devices, the potential for labeling as a complementary diagnostic, and the biomarker qualification program.

Recent Developments

  • In August 2022, F. Hoffmann-La Roche Ltd, announced the launch of the Digital LightCycler System, Roche's first digital polymerase chain reaction (PCR) system. This next-generation system detects disease and is designed to accurately quantify trace amounts of specific DNA and RNA targets not typically detectable by conventional PCR methods. This has helped the company to increase its Asia-Pacific presence in the market
  • In May 2022, Thermo Fisher Scientific Inc., the world leader in serving science, introduced the Thermo Scientific Glacios 2 Cryo-Transmission Electron Microscope (Cryo-TEM), a powerful microscope with new automation and high-resolution imaging capabilities designed to help cryo-electron microscopy (cryo-EM) researchers of varying experience levels accelerate structure-based drug discovery. This advanced, fast, and cost-efficient method for drug design may enable customers to accelerate the pace of research for debilitating disorders like Alzheimer's, Parkinson's, and Huntington's diseases, as well as research for cancer and gene mutations

Asia-Pacific Thyroid Cancer Diagnostics Market Scope

The Asia-Pacific thyroid cancer diagnostics market is segmented into product type, test type, cancer type, stages, age group, end user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.

Product Type

  • Instruments
  • Consumables & Accessories

On the basis of product type, the Asia-Pacific thyroid cancer diagnostics market is segmented into instruments and consumables & accessories.

Test Type

  • Imaging Test
  • Blood Test
  • Biopsy
  • Others

On the basis of test type, the Asia-Pacific thyroid cancer diagnostics market is segmented into imaging test, blood test, biopsy and others.

Cancer Type

  • Papillary Carcinoma
  • Follicular Carcinoma
  • Others

On the basis of cancer type, the Asia-Pacific thyroid cancer diagnostics market is segmented into papillary carcinoma, follicular carcinoma, and others.

Stages

  • Stage I
  • Stage II
  • Stage III
  • Stage IV

On the basis of stages, the Asia-Pacific thyroid cancer diagnostics market is segmented into stage I, stage II, stage III and stage IV.

Age Group

  • 30-65
  • 65 and above
  • 21-29
  • Below 21

On the basis of age group, the Asia-Pacific thyroid cancer diagnostics market is segmented into 30-65, 65 and above, 21-29, and below 21.

End User

  • Hospitals
  • Associated Labs
  • Independent Diagnostic Laboratories
  • Diagnostic Imaging Centers
  • Cancer Research Institutes
  • Others

On the basis of end user, the Asia-Pacific thyroid cancer diagnostics market is segmented into hospitals, associated labs, independent diagnostic laboratories, diagnostic imaging centers, cancer research institutes, and others.

Distribution Channel

  • Direct Tender
  • Retail Sales

On the basis of distribution channel, the Asia-Pacific thyroid cancer diagnostics market is segmented into direct tender and retail sales.

Thyroid Cancer Diagnostics Market

Asia-Pacific Thyroid Cancer Diagnostics Market Regional Analysis/Insights  

The Asia-Pacific thyroid cancer diagnostics market is analysed, and market size insights and trends are provided by country, product type, test type, cancer type, stages, age group, end user, and distribution channel, as referenced above.

The countries covered in this market report are Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, and the Rest of Asia-Pacific

China is expected to dominate the Asia-Pacific thyroid cancer diagnostics market in terms of market share and revenue and will continue to dominate during the forecast period. This is due to a rising preference for preventive health check-ups.

The country section of the report also provides individual market-impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of Asia-Pacific brands and their challenges faced due to competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Asia-Pacific Thyroid Cancer Diagnostics Market Share Analysis

Asia-Pacific thyroid cancer diagnostics market competitive landscape provides details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Asia-Pacific presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus related to the Asia-Pacific thyroid cancer diagnostics market.

Some of the major players operating in the Asia-Pacific thyroid cancer diagnostics market are Canon Inc., FUJIFILM Holdings Corporation, F. Hoffmann-La Roche Ltd, Quest Diagnostics Incorporated, Illumina, Koninklijke Philips N.V., Thermo Fisher Scientific Inc., Siemens Healthcare GmbH, Abbott, General Electric Company, BD, QIAGEN, DIASORIN S.P.A., Merck KGaA, Hologic, Myriad Genetics Inc., BIOMERIEUX, FONAR Corp., Time Medical Holding., PlexBio., MinFound Medical Systems Co., Ltd, Medonica Co. LTD, Beijing O&D Biotech Co., Ltd., and SternMed GmbH. among others.


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET TESTING TYPE COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER’S FIVE FORCES

4.3 GROWTH STRATEGIES ADOPTED BY KEY MARKET PLAYERS

5 EPIDEMIOLOGY

6 REGULATORY FRAMEWORK OF THE ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET

6.1 REGULATORY SCENARIO IN THE U.S.

6.2 REGULATORY SCENARIO IN AUSTRALIA

6.3 REGULATORY SCENARIO IN JAPAN

6.4 REGULATORY SCENARIO IN CHINA

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 RISING INCIDENCE AND PREVALENCE OF THYROID NODULES AND CANCER

7.1.2 RISING THYROID CANCER DIAGNOSTIC TESTS

7.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS

7.1.4 RISING AWARENESS TOWARDS THYROID CANCER

7.2 RESTRAINTS

7.2.1 HIGH COST OF DIAGNOSTICS PROCEDURE

7.2.2 TISSUE DAMAGE DUE TO HIGH RADIATION EXPOSURE FROM IMAGING TESTS

7.3 OPPORTUNITIES

7.3.1 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT

7.3.2 RISING OBESE POPULATION

7.4 CHALLENGES

7.4.1 STRINGENT REGULATORY FRAMEWORK FOR THE APPROVAL AND COMMERCIALIZATION OF CANCER DIAGNOSTIC PRODUCTS

7.4.2 LACK OF SKILLED AND CERTIFIED EXPERTISE

8 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE

8.1 OVERVIEW

8.2 INSTRUMENTS

8.2.1 PATHOLOGY BASED INSTRUMENTS

8.2.1.1 PCR INSTRUMENTS

8.2.1.2 SLIDE STAINING SYSTEMS

8.2.1.3 TISSUE PROCESSING SYSTEMS

8.2.1.4 CELL PROCESSORS

8.2.1.5 OTHER PATHOLOGY-BASED INSTRUMENTS

8.2.2 IMAGING INSTRUMENTS

8.2.2.1 ULTRASOUND SYSTEMS

8.2.2.2 CT SYSTEMS

8.2.2.3 MRI SYSTEMS

8.2.2.4 OTHERS

8.2.3 BIOPSY INSTRUMENTS

8.2.3.1 NEEDLE BIOPSY

8.2.3.2 ENDOSCOPIC BIOPSY

8.2.3.3 CORE BIOPSY

8.2.3.4 OTHERS

8.2.4 OTHERS

8.3 CONSUMABLES & ACCESSORIES

8.3.1 KITS

8.3.1.1 PCR KITS

8.3.1.2 DNA POLYMERASE KITS

8.3.1.3 NUCLEIC ACID ISOLATION KITS

8.3.1.4 OTHERS

8.3.2 REAGENTS

8.3.2.1 ASSAYS

8.3.2.2 BUFFERS

8.3.2.3 PRIMERS

8.3.2.4 OTHERS

8.3.3 PROBES

8.3.4 OTHER CONSUMABLES

9 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE

9.1 OVERVIEW

9.2 IMAGING TEST

9.2.1 COMPUTED TOMOGRAPHY (CT) SCAN

9.2.2 MRI

9.2.3 POSITRON EMISSION TOMOGRAPHY (PET) SCAN

9.2.4 OTHERS

9.3 BLOOD TEST

9.3.1 BLOOD CHEMISTRY TESTS

9.3.2 COMPLETE BLOOD COUNT (CBC)

9.3.3 OTHERS

9.4 BIOPSY

9.4.1 NEEDLE BIOPSY

9.4.2 BRONCHOSCOPY BIOPSY

9.4.3 CORE BIOPSY

9.4.4 OTHERS

9.5 OTHERS

10 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET, BY CANCER TYPE

10.1 OVERVIEW

10.2 PAPILLARY CARCINOMA

10.3 FOLLICULAR CARCINOMA

10.4 OTHERS

11 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET, BY STAGES

11.1 OVERVIEW

11.2 STAGE I

11.3 STAGE II

11.4 STAGE III

11.5 STAGE IV

12 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET, BY AGE GROUP

12.1 OVERVIEW

12.2 30-65

12.3 65 AND ABOVE

12.4 21-29

12.5 BELOW 21

13 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET, BY END USER

13.1 OVERVIEW

13.2 HOSPITALS

13.3 ASSOCIATED LABS

13.4 INDEPENDENT DIAGNOSTIC LABORATORIES

13.5 DIAGNOSTIC IMAGING CENTERS

13.6 CANCER RESEARCH INSTITUTES

13.7 OTHERS

14 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL

14.1 OVERVIEW

14.2 DIRECT TENDER

14.3 RETAIL SALES

15 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET, BY REGION

15.1 ASIA-PACIFIC

15.1.1 JAPAN

15.1.2 CHINA

15.1.3 SOUTH KOREA

15.1.4 INDIA

15.1.5 THAILAND

15.1.6 SINGAPORE

15.1.7 INDONESIA

15.1.8 MALAYSIA

15.1.9 PHILIPPINES

15.1.10 AUSTRALIA

15.1.11 VIETNAM

15.1.12 REST OF ASIA-PACIFIC

16 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE

16.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC

17 SWOT ANALYSIS

18 COMPANY PROFILE

18.1 CANON INC.

18.1.1 COMPANY SNAPSHOT

18.1.2 COMPANY SHARE ANALYSIS

18.1.3 PRODUCT PORTFOLIO

18.1.4 RECENT DEVELOPMENTS

18.2 FUJIFILM CORPORATION

18.2.1 COMPANY SNAPSHOT

18.2.2 REVENUE ANALYSIS

18.2.3 COMPANY SHARE ANALYSIS

18.2.4 PRODUCT PORTFOLIO

18.2.5 RECENT DEVELOPMENT

18.3 F. HOFFMANN-LA ROCHE LTD

18.3.1 COMPANY SNAPSHOT

18.3.2 REVENUE ANALYSIS

18.3.3 COMPANY SHARE ANALYSIS

18.3.4 PRODUCT PORTFOLIO

18.3.5 RECENT DEVELOPMENT

18.4 QUEST DIAGNOSTICS INCORPORATED

18.4.1 COMPANY SNAPSHOT

18.4.2 REVENUE ANALYSIS

18.4.3 COMPANY SHARE ANALYSIS

18.4.4 PRODUCT PORTFOLIO

18.4.5 RECENT DEVELOPMENTS

18.5 ILLUMINA, INC.

18.5.1 COMPANY SNAPSHOT

18.5.2 REVENUE ANALYSIS

18.5.3 COMPANY SHARE ANALYSIS

18.5.4 PRODUCT PORTFOLIO

18.5.5 RECENT DEVELOPMENT

18.6 ABBOTT

18.6.1 COMPANY SNAPSHOT

18.6.2 REVENUE ANALYSIS

18.6.3 PRODUCT PORTFOLIO

18.6.4 RECENT DEVELOPMENT

18.7 BD

18.7.1 COMPANY SNAPSHOT

18.7.2 REVENUE ANALYSIS

18.7.3 PRODUCT PORTFOLIO

18.7.4 RECENT DEVELOPMENT

18.8 BEIJING O&D BIOTECH CO., LTD.

18.8.1 COMPANY SNAPSHOT

18.8.2 PRODUCT PORTFOLIO

18.8.3 RECENT DEVELOPMENTS

18.9 BIOMÉRIEUX SA

18.9.1 COMPANY SNAPSHOT

18.9.2 REVENUE ANALYSIS

18.9.3 PRODUCT PORTFOLIO

18.9.4 RECENT DEVELOPMENTS

18.1 DIASORIN S.P.A.

18.10.1 COMPANY SNAPSHOT

18.10.2 REVENUE ANALYSIS

18.10.3 PRODUCT PORTFOLIO

18.10.4 RECENT DEVELOPMENT

18.11 FONAR CORP.

18.11.1 COMPANY SNAPSHOT

18.11.2 REVENUE ANALYSIS

18.11.3 PRODUCT PORTFOLIO

18.11.4 RECENT DEVELOPMENTS

18.12 GENERAL ELECTRIC

18.12.1 COMPANY SNAPSHOT

18.12.2 REVENUE ANALYSIS

18.12.3 PRODUCT PORTFOLIO

18.12.4 RECENT DEVELOPMENTS

18.13 HOLOGIC INC.

18.13.1 COMPANY SNAPSHOT

18.13.2 REVENUE ANALYSIS

18.13.3 PRODUCT PORTFOLIO

18.13.4 RECENT DEVELOPMENT

18.14 KONINKLIJKE PHILIPS N.V.

18.14.1 COMPANY SNAPSHOT

18.14.2 REVENUE ANALYSIS

18.14.3 PRODUCT PORTFOLIO

18.14.4 RECENT DEVELOPMENT

18.15 MERCK KGAA.

18.15.1 COMPANY SNAPSHOT

18.15.2 REVENUE ANALYSIS

18.15.3 PRODUCT PORTFOLIO

18.15.4 RECENT DEVELOPMENT

18.16 MEDONICA CO. LTD

18.16.1 COMPANY SNAPSHOT

18.16.2 PRODUCT PORTFOLIO

18.16.3 RECENT DEVELOPMENT

18.17 MINFOUND MEDICAL SYSTEMS CO. LTD

18.17.1 COMPANY SNAPSHOT

18.17.2 PRODUCT PORTFOLIO

18.17.3 RECENT DEVELOPMENTS

18.18 MYRIAD GENETICS, INC.

18.18.1 COMPANY SNAPSHOT

18.18.2 REVENUE ANALYSIS

18.18.3 PRODUCT PORTFOLIO

18.18.4 RECENT DEVELOPMENTS

18.19 PLEXBIO.

18.19.1 COMPANY SNAPSHOT

18.19.2 PRODUCT PORTFOLIO

18.19.3 RECENT DEVELOPMENTS

18.2 QIAGEN

18.20.1 COMPANY SNAPSHOT

18.20.2 REVENUE ANALYSIS

18.20.3 PRODUCT PORTFOLIO

18.20.4 RECENT DEVELOPMENT

18.21 STERNMED GMBH

18.21.1 COMPANY SNAPSHOT

18.21.2 PRODUCT PORTFOLIO

18.21.3 RECENT DEVELOPMENTS

18.22 SIEMENS HEALTHCARE GMBH

18.22.1 COMPANY SNAPSHOT

18.22.2 REVENUE ANALYSIS

18.22.3 PRODUCT PORTFOLIO

18.22.4 RECENT DEVELOPMENT

18.23 TIME MEDICAL HOLDING.

18.23.1 COMPANY SNAPSHOT

18.23.2 PRODUCT PORTFOLIO

18.23.3 RECENT DEVELOPMENT

18.24 THERMO FISHER SCIENTIFIC INC.

18.24.1 COMPANY SNAPSHOT

18.24.2 REVENUE ANALYSIS

18.24.3 PRODUCT PORTFOLIO

18.24.4 RECENT DEVELOPMENT

19 QUESTIONNAIRE

20 RELATED REPORTS

List of Table

TABLE 1 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 2 ASIA PACIFIC INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 3 ASIA PACIFIC INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 4 ASIA PACIFIC PATHOLOGY-BASED INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 5 ASIA PACIFIC IMAGING INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 6 ASIA PACIFIC BIOPSY INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 7 ASIA PACIFIC CONSUMABLES & ACCESSORIES IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 8 ASIA PACIFIC CONSUMABLES & ACCESSORIES IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 9 ASIA PACIFIC KITS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 10 ASIA PACIFIC REAGENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 11 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 12 ASIA PACIFIC IMAGING TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 13 ASIA PACIFIC IMAGING TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 14 ASIA PACIFIC BLOOD TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 15 ASIA PACIFIC BLOOD TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 16 ASIA PACIFIC BIOPSY IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 17 ASIA PACIFIC BIOPSY IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 18 ASIA PACIFIC OTHERS IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 19 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 20 ASIA PACIFIC PAPILLARY CARCINOMA IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 21 ASIA PACIFIC FOLLICULAR CARCINOMA IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 22 ASIA PACIFIC OTHERS IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 23 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 24 ASIA PACIFIC STAGE I IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 25 ASIA PACIFIC STAGE II IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 26 ASIA PACIFIC STAGE III IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 27 ASIA PACIFIC STAGE IV IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 28 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 29 ASIA PACIFIC 30-65 IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 30 ASIA PACIFIC 65 AND ABOVE IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 31 ASIA PACIFIC 21-29 IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 32 ASIA PACIFIC BELOW 21 IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 33 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 34 ASIA PACIFIC HOSPITALS IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 35 ASIA PACIFIC ASSOCIATED LABS IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 36 ASIA PACIFIC INDEPENDENT DIAGNOSTIC LABORATORIES IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 37 ASIA PACIFIC DIAGNOSTIC IMAGING CENTERS IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 38 ASIA PACIFIC CANCER RESEARCH INSTITUTES IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 39 ASIA PACIFIC OTHERS IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 40 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 41 ASIA PACIFIC DIRECT TENDER IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 42 ASIA PACIFIC RETAIL SALES IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 43 ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 44 ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 45 ASIA-PACIFIC INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 46 ASIA-PACIFIC PATHOLOGY-BASED INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 47 ASIA-PACIFIC IMAGING INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 48 ASIA-PACIFIC BIOPSY INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 49 ASIA-PACIFIC CONSUMABLES & ACCESSORIES IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 50 ASIA-PACIFIC KITS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 51 ASIA-PACIFIC REAGENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 52 ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 53 ASIA-PACIFIC IMAGING TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 54 ASIA-PACIFIC BIOPSY IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 55 ASIA-PACIFIC BLOOD TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 56 ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 57 ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 58 ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 59 ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 60 ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 61 JAPAN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 62 JAPAN INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 63 JAPAN PATHOLOGY-BASED INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 64 JAPAN IMAGING INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 65 JAPAN BIOPSY INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 66 JAPAN CONSUMABLES & ACCESSORIES IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 67 JAPAN KITS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 68 JAPAN REAGENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 69 JAPAN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 70 JAPAN IMAGING TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 71 JAPAN BIOPSY IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 72 JAPAN BLOOD TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 73 JAPAN THYROID CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 74 JAPAN THYROID CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 75 JAPAN THYROID CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 76 JAPAN THYROID CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 77 JAPAN THYROID CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 78 CHINA THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 79 CHINA INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 80 CHINA PATHOLOGY-BASED INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 81 CHINA IMAGING INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 82 CHINA BIOPSY INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 83 CHINA CONSUMABLES & ACCESSORIES IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 84 CHINA KITS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 85 CHINA REAGENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 86 CHINA THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 87 CHINA IMAGING TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 88 CHINA BIOPSY IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 89 CHINA BLOOD TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 90 CHINA THYROID CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 91 CHINA THYROID CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 92 CHINA THYROID CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 93 CHINA THYROID CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 94 CHINA THYROID CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 95 SOUTH KOREA THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 96 SOUTH KOREA INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 97 SOUTH KOREA PATHOLOGY-BASED INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 98 SOUTH KOREA IMAGING INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 99 SOUTH KOREA BIOPSY INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 100 SOUTH KOREA CONSUMABLES & ACCESSORIES IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 101 SOUTH KOREA KITS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 102 SOUTH KOREA REAGENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 103 SOUTH KOREA THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 104 SOUTH KOREA IMAGING TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 105 SOUTH KOREA BIOPSY IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 106 SOUTH KOREA BLOOD TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 107 SOUTH KOREA THYROID CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 108 SOUTH KOREA THYROID CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 109 SOUTH KOREA THYROID CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 110 SOUTH KOREA THYROID CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 111 SOUTH KOREA THYROID CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 112 INDIA THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 113 INDIA INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 114 INDIA PATHOLOGY-BASED INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 115 INDIA IMAGING INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 116 INDIA BIOPSY INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 117 INDIA CONSUMABLES & ACCESSORIES IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 118 INDIA KITS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 119 INDIA REAGENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 120 INDIA THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 121 INDIA IMAGING TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 122 INDIA BIOPSY IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 123 INDIA BLOOD TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 124 INDIA THYROID CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 125 INDIA THYROID CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 126 INDIA THYROID CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 127 INDIA THYROID CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 128 INDIA THYROID CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 129 THAILAND THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 130 THAILAND INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 131 THAILAND PATHOLOGY-BASED INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 132 THAILAND IMAGING INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 133 THAILAND BIOPSY INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 134 THAILAND CONSUMABLES & ACCESSORIES IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 135 THAILAND KITS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 136 THAILAND REAGENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 137 THAILAND THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 138 THAILAND IMAGING TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 139 THAILAND BIOPSY IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 140 THAILAND BLOOD TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 141 THAILAND THYROID CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 142 THAILAND THYROID CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 143 THAILAND THYROID CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 144 THAILAND THYROID CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 145 THAILAND THYROID CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 146 SINGAPORE THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 147 SINGAPORE INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 148 SINGAPORE PATHOLOGY-BASED INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 149 SINGAPORE IMAGING INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 150 SINGAPORE BIOPSY INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 151 SINGAPORE CONSUMABLES & ACCESSORIES IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 152 SINGAPORE KITS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 153 SINGAPORE REAGENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 154 SINGAPORE THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 155 SINGAPORE IMAGING TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 156 SINGAPORE BIOPSY IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 157 SINGAPORE BLOOD TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 158 SINGAPORE THYROID CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 159 SINGAPORE THYROID CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 160 SINGAPORE THYROID CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 161 SINGAPORE THYROID CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 162 SINGAPORE THYROID CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 163 INDONESIA THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 164 INDONESIA INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 165 INDONESIA PATHOLOGY-BASED INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 166 INDONESIA IMAGING INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 167 INDONESIA BIOPSY INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 168 INDONESIA CONSUMABLES & ACCESSORIES IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 169 INDONESIA KITS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 170 INDONESIA REAGENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 171 INDONESIA THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 172 INDONESIA IMAGING TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 173 INDONESIA BIOPSY IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 174 INDONESIA BLOOD TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 175 INDONESIA THYROID CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 176 INDONESIA THYROID CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 177 INDONESIA THYROID CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 178 INDONESIA THYROID CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 179 INDONESIA THYROID CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 180 MALAYSIA THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 181 MALAYSIA INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 182 MALAYSIA PATHOLOGY-BASED INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 183 MALAYSIA IMAGING INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 184 MALAYSIA BIOPSY INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 185 MALAYSIA CONSUMABLES & ACCESSORIES IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 186 MALAYSIA KITS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 187 MALAYSIA REAGENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 188 MALAYSIA THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 189 MALAYSIA IMAGING TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 190 MALAYSIA BIOPSY IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 191 MALAYSIA BLOOD TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 192 MALAYSIA THYROID CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 193 MALAYSIA THYROID CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 194 MALAYSIA THYROID CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 195 MALAYSIA THYROID CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 196 MALAYSIA THYROID CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 197 PHILIPPINES THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 198 PHILIPPINES INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 199 PHILIPPINES PATHOLOGY-BASED INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 200 PHILIPPINES IMAGING INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 201 PHILIPPINES BIOPSY INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 202 PHILIPPINES CONSUMABLES & ACCESSORIES IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 203 PHILIPPINES KITS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 204 PHILIPPINES REAGENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 205 PHILIPPINES THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 206 PHILIPPINES IMAGING TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 207 PHILIPPINES BIOPSY IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 208 PHILIPPINES BLOOD TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 209 PHILIPPINES THYROID CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 210 PHILIPPINES THYROID CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 211 PHILIPPINES THYROID CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 212 PHILIPPINES THYROID CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 213 PHILIPPINES THYROID CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 214 AUSTRALIA THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 215 AUSTRALIA INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 216 AUSTRALIA PATHOLOGY-BASED INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 217 AUSTRALIA IMAGING INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 218 AUSTRALIA BIOPSY INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 219 AUSTRALIA CONSUMABLES & ACCESSORIES IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 220 AUSTRALIA KITS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 221 AUSTRALIA REAGENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 222 AUSTRALIA THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 223 AUSTRALIA IMAGING TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 224 AUSTRALIA BIOPSY IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 225 AUSTRALIA BLOOD TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 226 AUSTRALIA THYROID CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 227 AUSTRALIA THYROID CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 228 AUSTRALIA THYROID CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 229 AUSTRALIA THYROID CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 230 AUSTRALIA THYROID CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 231 VIETNAM THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 232 VIETNAM INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 233 VIETNAM PATHOLOGY-BASED INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 234 VIETNAM IMAGING INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 235 VIETNAM BIOPSY INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 236 VIETNAM CONSUMABLES & ACCESSORIES IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 237 VIETNAM KITS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 238 VIETNAM REAGENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 239 VIETNAM THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 240 VIETNAM IMAGING TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 241 VIETNAM BIOPSY IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 242 VIETNAM BLOOD TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 243 VIETNAM THYROID CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 244 VIETNAM THYROID CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 245 VIETNAM THYROID CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 246 VIETNAM THYROID CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 247 VIETNAM THYROID CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 248 REST OF ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

List of Figure

FIGURE 1 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: SEGMENTATION

FIGURE 2 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION

FIGURE 3 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: DROC ANALYSIS

FIGURE 4 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS

FIGURE 5 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID

FIGURE 8 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: MARKET TESTING TYPE COVERAGE GRID

FIGURE 9 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: SEGMENTATION

FIGURE 11 THE INCREASE IN THE AWARENESS ABOUT THYROID CANCER IS EXPECTED TO DRIVE THE ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET IN THE FORECAST PERIOD

FIGURE 12 PRODUCT TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET IN 2023 & 2030

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET

FIGURE 14 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2022

FIGURE 15 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)

FIGURE 16 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2023-2030)

FIGURE 17 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE

FIGURE 18 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2022

FIGURE 19 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION)

FIGURE 20 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030)

FIGURE 21 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE

FIGURE 22 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2022

FIGURE 23 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2023-2030 (USD MILLION)

FIGURE 24 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2023-2030)

FIGURE 25 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE

FIGURE 26 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY STAGES, 2022

FIGURE 27 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY STAGES, 2023-2030 (USD MILLION)

FIGURE 28 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY STAGES, CAGR (2023-2030)

FIGURE 29 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY STAGES, LIFELINE CURVE

FIGURE 30 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2022

FIGURE 31 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2023-2030 (USD MILLION)

FIGURE 32 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY AGE GROUP, CAGR (2023-2030)

FIGURE 33 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY AGE GROUP, LIFELINE CURVE

FIGURE 34 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY END USER, 2022

FIGURE 35 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION)

FIGURE 36 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030)

FIGURE 37 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE

FIGURE 38 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022

FIGURE 39 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

FIGURE 40 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 41 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 42 ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)

FIGURE 43 ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)

FIGURE 44 ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)

FIGURE 45 ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)

FIGURE 46 ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET: PRODUCT TYPE (2023-2030)

FIGURE 47 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)

View Detailed Information Right Arrow

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The Asia-Pacific thyroid cancer diagnostics market size will be worth USD 1,572.00 million by 2030.
The growth rate of the Asia-Pacific thyroid cancer diagnostics market is 5.0% in the forecast period by 2030.
Rising incidence and prevalence of thyroid nodules & cancer & rising thyroid cancer diagnostic tests are the growth drivers of the Asia-Pacific thyroid cancer diagnostics market.
Product type, test type, cancer type, stages, age group, end user, and distribution channel are the factors on which the Asia-Pacific thyroid cancer diagnostics market research is based.
Major companies in the Asia-Pacific thyroid cancer diagnostics market are Canon Inc., FUJIFILM Holdings Corporation, F. Hoffmann-La Roche Ltd, Quest Diagnostics Incorporated, Illumina, Koninklijke Philips N.V., Thermo Fisher Scientific Inc., Siemens Healthcare GmbH, Abbott, General Electric Company, BD, QIAGEN, DIASORIN S.P.A., Merck KGaA, Hologic, Myriad Genetics Inc., BIOMERIEUX, FONAR Corp., Time Medical Holding., PlexBio., MinFound Medical Systems Co., Ltd, Medonica Co. LTD, Beijing O&D Biotech Co., Ltd., and SternMed GmbH. among others.